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Edited by Barry HalliwellAbstract Antioxidant protein Peroxiredoxin V (PrxV) is
located in mitochondria and peroxisomes but is also present in
the nucleus. Here, we show that nuclear PrxV associates with
coilin-containing bodies suggesting possible interaction of this
protein with transcription complexes. We also studied etoposide-
induced phosphorylation of histone H2AX (c-H2AX) in human
cells in which PrxV activity was downregulated (knockdown,
KD-clones) or compromised by overexpression of redox-negative
(RD) protein. In KD clones, but not in RD-clones, formation of
etoposide-induced c-H2AX was increased, indicating that PrxV
inhibits conversion of topoisomerase II cleavage complexes into
double-strand DNA breaks but this inhibition is not caused by its
antioxidant activity.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Peroxiredoxins belong to the recently identiﬁed protein
family, which play an important role in antioxidant defense
and in hydrogen peroxide-mediated signaling (rev. in [1–3]).
These proteins contain one or two redox-active cysteine resi-
dues which can be oxidized to a sulphenic acid by a peroxide
substrate and then recycled back to a thiol [1]. Peroxiredoxins I
and II (PrxI and PrxII) are shown to be essential for antioxi-
dant protection of red blood cells in mice [4,5] and for pro-
tection of mammalian cells against ionizing radiation [6,7].
Human PrxV gene has been originally cloned in 1997 as a
gene, which is downregulated in adenovirus-infected cells
(Genbank Accession Nos. U82615, U82616). In 1999 the full
cDNA for this gene was isolated, sequenced and identiﬁed as
gene, which product is able to repress RNA polymerase III-* Corresponding author. Fax: +7-812-2470341.
E-mail address: nvtom@mail.ru (N.V. Tomilin).
Abbreviations: PrxV, peroxiredoxin V; NES, nuclear export signal;
RN, redox-negative; KD, knockdown; DTT, dithiothreitol; PBS,
phosphate-buﬀered saline; c-H2AX, Ser-139 phosphorylated histone
H2AX
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doi:10.1016/j.febslet.2004.07.011dependent transcription of Alu retroposons in vitro [8]. Later
in 1999 identical genes have been independently cloned as
genes encoding a peroxisomal antioxidant protein [9] and a
major antioxidant protein of bronchoalveolar lavage ﬂuid [10].
PrxV contains C-terminal peroxisome-targeting signal 1 al-
lowing this protein to concentrate in peroxisomes [8,9]. Nev-
ertheless, signiﬁcant amount of PrxV is also present in
mitochondria [10], cytosol and in the nuclei [8]. Mouse PrxV
was shown to be able to suppress p53-dependent apoptosis of
cultivated cells [11] and human PrxV was able to promote
diﬀerentiation and reduce apoptosis in the muscle cells of mice
[12]. PrxV is also demonstrated to have antioxidant functions
in some mammalian tissues like lung, cartilage and brain [13–
16]. However, it still remains unknown whether antioxidant
defense is the only function of this protein. Since signiﬁcant
amount of PrxV is found in the nucleus [8,17] where it may
have antioxidant function, this protein may also play a role in
regulation of transcription because of its direct protein–protein
interactions with transcription factors [8]. For example, PrxI
(also named Pag protein) interacts with box II domain of the c-
Myc protein which is important for transcriptional regulation
[18].
In this study, we constructed and analyzed two types of
stable clones of human cells with impaired PrxV activity: (1)
clones with downregulation of overall amount of PrxV protein
using siRNA technology (knockdown, KD-clones), (2) clones
with overexpression of redox-negative PrxV variant (RN-
clones) in which only antioxidant activity of this protein was
compromised. Both types of clones show an increased amount
of intracellular ROS. However, the comparison of the amount
of etoposide-induced double-strand breaks in these clones re-
vealed that they diﬀerentially respond to this drug, suggesting
the involvement of a non-redox acivity of PrxV. We also found
that a fraction of PrxV associates with distinct nuclear bodies
containing p80 coilin consistent with possible interactions of
PrxV with transcription complexes.2. Materials and methods
2.1. Construction of siRNA plasmids
Vector mU6pro with U6 RNA gene promoter was obtained from
Dr. D.L. Turner (map can be found http://sitemaker.umich.edu/
dlturner.vectors/rna_interference_vectors ). siRNA encoding synthetic
oligonucleotides were subcloned between BbsI and XbaI restriction
sites. NEO gene was ampliﬁed using PCR from the Rc-CMV plasmidation of European Biochemical Societies.
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of siRNA oligonucleotides were identiﬁed using PCR and sequenced
with vector primers GCTACATTTTACATGATAGGCTTGG
(U6-forward) and CACAGGAAACAGCTATGACCAT (M13-rev).
Sequences (50 to 30) of siRNA complementary oligonucleotides for
control GFP (green ﬂuorescence protein) gene and PrxV gene (hairpin
is shown in italic) are given below:
GFP5-top: TTTGAAGAAGTCGTGCTGCTTCATGGAAGCA-
GCACGACTTCTTCTTTTT
GFP5-bottom: CTAGAAAAAGAAGAAGTCGTGCTGCTTC-
CATGAAGCAGCACGACTTCTT
PrxV-top: TTTGAGAACCTCTTGAGACGTCGATGACGTC-
TCAAGAGGTTCTCTTTTT
PrxV-bottom: CTAGAAAAAGAGAACCTCTTGAGACGTCAT-
CGACGTCTCAAGAGGTTCT
2.2. Construction of plasmid expressing RN PrxV and puriﬁcation of
the recombinant proteins
Human PrxV cDNA fragment containing the coding mitochondrial
targeting sequence (Genbank sequence ﬁle AF231705) was ﬁrst sub-
cloned in proper orientation into unique BamHI site of the bacterial
expression vector pQE30 (Qiagen). To isolate the plasmid encoding
RN PrxV, we used standard Oligonucleotide Site-directed Mutagenesis
method with mutated PrxV oligonucleotide 50 ccttcacccctg-
gaTCTtccaagacacacc 30 in which normal TGT codon encoding redox
active Cysteine-100 was replaced by TCT codon encoding redox-in-
active Serine-100. Replacement of this codon in the resulting plasmid
pQE-PrxV-RN was conﬁrmed by sequencing. Further, human PrxV
and PrxV-RN were expressed in Escherichia coli strain TG1 with their
mitochondrial presequence as 6  His-tagged proteins and puriﬁed as
described previously [8].
For the construction of pPrxV-RN-IRES-Neo, human PrxV-RN
cDNA was ampliﬁed from pQE-PrxV-RN plasmid by PCR using
forward primer 50 TCA CGA ATT CAG TGG CCG TGG GGC
GGG T 30 (EcoRI site underlined) and reverse primer 50 CCA
AGG ATC CAT TTG CAG GGC CCC AG 30 (BamH1 site under-
lined) and cloned into EcoRI and BamH1 sites of pIRES-Neo (Clon-
tech).2.3. Cell culture
HeLa and non-small lung carcinoma U1810 cells were cultivated in
DMEM containing D-glucose (4.5 g/l) and supplemented with 10%
fetal calf serum (FCS), 100 U/ml penicillin, and 100 lg/ml strepto-
mycin (complete DMEM) in a 95% humidiﬁed atmosphere, in 5% CO2
at 37 C. Cells were passaged at a 1:10 ratio every 5 days with 0.05%
trypsin–EDTA.
2.4. Isolation of stable clones of U1810 cells
U1810, a non-small cell lung carcinoma cells, grown on 24-well plate
were transfected either with redox negative mutant PrxV-RN in
pIRES-Neo or with mU6neo, which expressed siRNA against PrxV
using Lipofectamine 2000 obtained from INVITROGEN. 0.8 lg of
plasmid DNA or 1.6 ll of Lipofectamine was diluted in 50 ll of Opti-
MEM, incubated for 5 min, then mixed and incubated for 20 min
before addition to cells. After overnight incubation at 37 C in CO2
incubator DMEM plus 10% FCS were added, incubation continued
for 10 h, then cells were re-plated at 1/10–1/40 dilution onto the 6-well
plates and selection with G418 (1 mg/ml) started on the next day.
Individual clones growing on G418 were analyzed using Western
blotting with antibodies to PrxV. Three of U1810 clones with over-
expression of PrxV-RN and three of these clones with decreased ex-
pression of PrxV as well as the mix of control clones obtained after
transfection of U1810 cells with either empty pIRES-neo vector or
GFP siRNA expressing mU6neo plasmid were used in preliminary
experiments and showed similar results. More detailed investigation
was performed using two clones of each variant and average data
obtained from three independent experiments using all these clones are
presented.
2.5. Immunoﬂuorescence analysis
Cells grown on microscopic slides were washed with phosphate-
buﬀered saline (PBS) and ﬁxed 15 min with 4% formaldehyde before or
after extraction with 0.1% solution of Triton X-100 in PBS for 1 min at
room temperature. After permeabilization with 0.1% Triton X-100 inPBS for 10 min, cells were incubated overnight at 4 C with the
combination of two of the following primary antibodies in 5% solution
of BSA in PBS: rabbit anti-human PrxV polyclonal antibodies (1/100)
aﬃnity puriﬁed as described in [8], and mouse anti-coilin monoclonal
antibodies (1:25, BD Biosciences). After rinsing 4 5 min in PBS, the
samples were incubated for 1 h with the following secondary anti-
bodies in 5% BSA in PBS and with 1 lg/ml Hoechst 33342 (Sigma):
TRITC-conjugated donkey anti-rabbit antibodies (1:175, Jackson) for
PrxV and CY2-conjugated goat anti-mouse antibodies (1:400, Amer-
sham Bioscience) for coilin. After ﬁnal rinsing 4 5 min in PBS, the
samples were mounted on glass slides using Pro-Long mountain
medium (Molecular Probes) and analyzed on Olympus ﬂuorescent
microscope.
2.6. FACS analysis of sub-G1 cells
Propidium iodide (PI) staining of cells was used for apoptosis studies
[19]. Control and transfected U1810 cells were seeded in 6-well plate
for 36 h. Apoptosis was induced by treatment with 0.5 mM hydrogen
peroxide or 8 Gy IR. After indicated times cells were collected by
trypsinization, washed once with cold PBS, mixed with 500 ll of hy-
potonic solution (0.1% sodium citrate, 0.1% Triton X-100, 100 lg/ml
RNAse, and 50 lg/ml PI) and analyzed by ﬂow cytometry after 60 min
incubation. Cells that had lost part of their DNA due to the DNA
fragmentation were detected as a population of cells with sub-G1
DNA contents (apoptotic cells).
2.7. Immunoblotting
The U1810 cell clones were cultivated in 6-well plates. At the stage of
70–90% conﬂuence, cells were treated with 10 lM etoposide for indi-
cated times, washed with PBS, resuspended in the Laemmli’s loading
buﬀer, harvested and heated at 95 C for 4 min. Twenty microliters of
each sample were resolved on 15% SDS–polyacrylamide gel and elec-
troblotted onto nitrocellulose membranes. Membranes were blocked
with PBS supplemented with 5% non-fat dry milk on a rocker for 1 h at
room temperature and then incubated overnight at 4 C with 1:10 000
mouse monoclonal anti-phospho-H2AX (Ser139) antibody (Upstate
Biotech #05–636) or 1:2500 rabbit anti-human PrxV polyclonal anti-
body or with 1:3000 rabbit anti-G3PDH, followed by incubation for 1
h with 1:10 000 peroxidase-conjugated goat anti-rabbit IgG or goat
anti-mouse IgG. Bands were visualized by ECL (Pharmacia Biotech)
according to the manufacturer’s instructions and detected by exposure
to X-ray ﬁlm. Densitometry was performed on ﬁlms using a GS-700
densitometer and ‘‘Quantity One’’ software (Bio-Rad, USA). Nor-
malization of c-H2AX and PrxV proteins levels was performed with
G3PDH levels.3. Results and discussion
PrxV has wide intracellular localization. It is mainly located
in mitochondria and cytoplasm [8,10] but signiﬁcant amount
of PrxV is also present in the nucleus [8,17]. During our studies
of localization of PrxV in formaldehyde-ﬁxed human cells,
besides the patterns of mitochondrial, cytoplasmic and ho-
mogeneous nuclear staining, we reproducibly observed distinct
nuclear bodies containing this protein resembling in size and
number of Cajal bodies. Marker protein for Cajal bodies is p80
protein coilin, and double labeling of untreated U1810 or
HeLa cells with anti-PrxV and anti-coilin antibodies showed
that the majority of nuclear PrxV colocalize with coilin-posi-
tive nuclear bodies (Fig. 1). Since Cajal bodies are known to
play a critical role in preassembly of transcription complexes
[20], we believe that PrxV may be involved in regulation of
transcription through its interaction with transcription com-
plexes. This may potentially explain the presence of signiﬁcant
amount of PrxV (both diﬀuse and punctate) in the nucleus
despite the absence of known nuclear import signals in this
protein. Interestingly, PrxV protein sequence contains poten-
tial nuclear export signal (NES), (ValGlyAspAlaIlePro-
AlaValGluVal) which ﬁts very well to the consensus NES
Fig. 1. Immunocytochemical staining of PrxV (red) and coilin (green)
in U1810 cells after Triton X-100 extraction and in HeLa cells without
the extraction (for details see Section 2). Counterstaining with Hoechst
33342 was performed (blue signal). Bar 10 lm.
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cine or valine and R represents any amino acids. PrxV-asso-
ciated NES may regulate transport of non-complexed nuclear
PrxV to the cytoplasm. Interestingly, PrxI, which like PrxV
lacks canonical nuclear localization signal, can be targeted to
the nucleus because of its direct interaction with c-Abl protein
[23].
To get insight into possible functions of PrxV, stable clones
of human cells with impaired PrxV activity were isolated. First,
we have constructed plasmid with replacement in full PrxV
cDNA of redox-active cysteine (Cys-100) for serine. This has
been done by primer extension of mutant oligonucleotide on aFig. 2. Characterization of U1810 cell clones with impaired PrxV activity. (A
catalase. The reaction mixture (200 ll) contained 50 mM HEPES–NaOH, pH
the remaining concentration of H2O2 was measured in 20 ll aliquots of react
and compared with standards. Data are the means of three experiments. (B)
antibodies against PrxV was performed with cell lysates (30 lg of total prote
against G3PDH were used for protein loading control. Quantitation of resul
intensities of DCFH probe in the U1810 clones. Bars represent mean values
independent experiments. (D) Cells were irradiated (8 Gy) or treated with 50
after 24 and 48 h. All values are means from three independent experiments. C
irradiation.PrxV cDNA plasmid template and selection of resulting bac-
terial clones by hybridization. Mutant cDNA fragment from
selected plasmid was then subcloned into bacterial (pQE-30)
and mammalian (pIRES-Neo) expression vectors and exami-
nation of bacterially expressed and puriﬁed protein conﬁrmed
inactivation of its peroxidase activity (Fig. 2A). Mammalian
expression plasmid with C100S PrxV was then used in trans-
fection of U1810 cells and selection of stable G418-resistant
clones. In two of these clones used in subsequent studies,
overexpression of redox-inactive PrxV resulted in approxi-
mately 2-fold increase of intracellular ROS, which was de-
tected by FACS analysis with dichloroﬂuorescein diacetate
(DCFH-DA) (Fig. 2C). This suggests that redox-inactive PrxV
might downregulate expression of endogenous redox-active
PrxV and compete with this protein in indicated clones (named
Redox Negative, RN-clones), thus suppressing its normal an-
tioxidant function. Overall amount of PrxV protein detected in
RN-clones by Western blotting with polyclonal antibodies,
which cannot discriminate redox-inactive from endogenous
PrxV, was found to be increased (Fig. 2B).
To isolate human PrxV KD clones expressing PrxV siRNA,
a vector with U6 RNA gene promoter (mU6-pro) was used
[24] into which we subcloned NEO gene and oligonucleotides
with inverted repeats from PrxV gene (see Section 2). The si-
lencing activity of resulting plasmid towards PrxV was con-
ﬁrmed by transient transfections of human 293 cells in which a
decrease of PrxV protein was detected by Western blotting
(not shown). This plasmid was introduced into U1810 cells and
G418-resistant clones were selected and analyzed for PrxV
content by Western blotting. Strong decrease of PrxV protein
was detected in stable KD clones of U1810 cells (Fig. 2B),
indicating that siRNA from the selected segment of PrxV gene
eﬃciently induces degradation of PrxV mRNA. In KD-clones,) Peroxidase activity of recombinant wtPrxV, C100SPrxV and bovine
7.4, 2 mM DTT, 0.12 mM H2O2 and proteins. At the indicated times,
ion mixture with ferrous ammonium sulfate/potassium thiocyanate [30]
Expression of PrxV protein in the U1810 clones. Western blotting with
in) prepared from the KD, RN and control U1810 clones. Antibodies
ts from three experiments is present on the right side. (C) Fluorescence
of cell ﬂuorescence relative control U1810 clone obtained from three
0 lM hydrogen peroxide and percent of the subG1 cells was measured
oncentration of NAC was 5 mM and this agent was added just before
Fig. 3. Induction of DSBs in genomic DNA in the U1810 clones after treatment with 10 lM etoposide. (A) The U1810 cell clones were treated with
etoposide at indicated time and formation of DSBs was analyzed by Western blotting using monoclonal anti-c-H2AX antibodies. (B) Bars represent
mean values of c-H2AX/G3PDH densitometry ratios ± S.D. obtained from three experiments. (C) Immunocytochemical staining of PrxV in U1810
RN clone (left image). The right image is DNA staining of the same cell with Hoechst 33342.
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1.9-fold increase of intracellular ROS (Fig. 2C).
For further characterization of isolated KD- and RN-clones,
their response to treatment with oxidative agents was studied.
Phenotypic consequences of downregulation of PrxV were
analyzed using measurement of the DNA fragmentation after
treatment with 500 lM hydrogen peroxide or c-irradiation (8
Gy). Fragmentation of DNA, indicator of the late events of
apoptosis, results in the appearance of cells containing subG1
level of DNA that can be detected by ﬂow cytometry analyses
of propidium iodide-stained cells [19]. Both KD- and RN-
clones contained signiﬁcantly increased fraction of sub-G1
cells 48 h after c-irradiation (8 Gy) or treatment with 500 lM
H2O2 compared to control cells (Fig. 2D), indicating that PrxV
suppresses radiation- and hydrogen peroxide-induced apop-
tosis in agreement with earlier reports [11,12]. However, eﬃ-
ciency of induction of apoptosis was higher in RN-clone
compared to KD-clone and clearly seen in RN-clone even 24 h
after cell damage (Fig. 2D). Since both RN- and KD-clones
show approximately the same increase of ROS (Fig. 2C), this
result suggests that not only antioxidant activity of PrxV may
be responsible for suppression of apoptosis by this protein.
Conﬁrming this view was our ﬁnding that the reducing agent
N-acetyl cysteine (NAC, 5 mM), which signiﬁcantly decreased
the amount of intracellular ROS, did not eﬀect radiation-in-
duced apoptosis in U1810 cells (Fig. 2D).
To investigate the possible role of PrxV in protection of cells
against non-oxidative DNA damage, we used well-known an-
ticancer agent, etoposide, which kills tumor cells by induction
of DNA double-strand breaks, DSBs [25]. This drug inhibits re-
ligation of topoisomerase II-induced DNA breaks and formed
topo II cleavage complexes that can be then converted to DSBs
through DNA unwinding during replication or transcription
[25]. Topo II is required for transcription elongation on chro-
matin template to relieve arising superhelical tension [26]. We
analyzed etoposide-induced DSBs in RN- and KD-clones by
Western blotting using antibodies against phosphorylated hi-
stone H2AX (c-H2AX), which is known to be formed atmegabase chromatin domains near DSBs [27,28] and which
presence strongly correlates with unrepaired DSBs in vivo [29].
c-H2AX can be detected in cells as early as 1 h after addition of
10 lM etoposide and maximal amount of c-H2AX was found
at 3–6 h after treatment with this drug (Fig. 3B). Signiﬁcant
increase of etoposide-induced c-H2AX was observed in KD-
clone at 3 and 6 h compared to parental U1810 cells (Fig. 3A
and B), suggesting that decreased amount of PrxV in KD cells
stimulated conversion of topo II cleavage complexes to DSBs.
Under similar experimental conditions about the same amount
of c-H2AX as in parental cells was detected in RN-clone
(Fig. 3B), suggesting that suppression of the antioxidant ac-
tivity of PrxV does not aﬀect etoposide-induced DSBs. The
absence of PrxV-mediated protection against etoposide-in-
duced DSBs in RN-clone is not a consequence of changed lo-
calization of this protein and PrxV can be easily detected in the
nucleus using indirect immunoﬂuorescence (Fig. 3C). Taken
together, these results suggest that PrxV-dependent suppression
of conversion of etoposide-induced cleavage complexes into
DSBs in human cells is not associated with the antioxidant
activity of PrxV but depends on another functional activity of
this protein in the nucleus. Since PrxV co-localized with Cajal
bodies and since PrxV gene has been originally cloned as po-
tential repressor of RNA polymerase III-dependent transcrip-
tion in vitro [8], it is likely that the ability of PrxV protein to
suppress formation of etoposide-induced DSBs (Fig. 3) is as-
sociated with its role in regulation of transcription in vivo.
Further studies of transcription in KD-clones and interactions
of PrxV with transcription complexes may be helpful to get
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